
Intra-Cellular Therapies has announced positive topline results from Study 501, which assessed lumateperone 42mg as an adjunctive therapy to antidepressants …

Biotech firm Intra-Cellular Therapies has appointed former NICE chairman Professor Sir Michael Rawlins to its Board of directors. Rawlins was …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

